KIMMTRAK Sales Forecast And Market Size Analysis - 2034 Report Tracks Sales Rising From $238.7M (2023) To $310M (2024) As The First Approved TCR Therapy For Cancer Expands Globally
Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "KIMMTRAK Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
The report assesses the commercial outlook for KIMMTRAK, Immunocore's bispecific gp100 peptide-HLA-directed CD3 T cell engager. It covers the seven major markets (7MM) over a 2020-2034 study period.
The "KIMMTRAK Sales Forecast, and Market Size Analysis - 2034" report provides a comprehensive assessment of KIMMTRAK across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. Covering the 2020-2034 study period, the report evaluates historical performance, current market adoption, anticipated commercial expansion, and sales forecasts for approved and potential indications, including uveal melanoma and malignant melanoma.
Key Facts
- 2023 sales: about $238.7 million 2024 sales: about $310 million Q4 2024 revenue: $84.1 million H1 2025 net product sales: $191.8 million, including $98.0 million in the three months ended June 2025 US sales (2024): more than $226 million Global footprint (as of 2024): approved in about 39 countries and launched in 24, including 14 new country launches in 2024 Regulatory approvals: FDA approval in January 2022, followed by EMA authorisation in 2022
A First-in-Class Immunotherapy
KIMMTRAK is the first approved T-cell receptor (TCR) therapy for cancer. It binds the gp100 peptide presented by HLA-A02:01 on tumour cells and CD3 on T cells, redirecting T cells to kill tumour cells. The report describes this as a new immunotherapy class beyond checkpoint inhibitors. KIMMTRAK is approved as monotherapy for HLA-A02:01-positive adults with unresectable or metastatic uveal melanoma (mUM).
Growth Drivers
The report identifies five factors behind KIMMTRAK's commercial momentum:
- its first-in-class differentiation the first overall survival improvement demonstrated in mUM, from a pivotal Phase III trial against investigator's choice therapy consistent sales growth rapid global expansion high unmet need in a cancer where median overall survival has historically been around 12 months
KIMMTRAK is now considered standard of care in most markets where it has launched.
Clinical and Commercial Considerations
KIMMTRAK is given intravenously, using a step-up dosing regimen followed by weekly dosing. Patients need hospitalisation and monitoring for cytokine release syndrome (CRS), which carries a boxed warning. The report examines these factors alongside pricing, cost per patient, and regional variation.
Competitive Landscape
The report reviews marketed therapies and late-stage emerging therapies in uveal melanoma and malignant melanoma, including their expected launch dates. It also assesses KIMMTRAK's market positioning, strengths, and weaknesses relative to these competitors.
Report Scope
The report covers:
- KIMMTRAK's mechanism of action, dosage, and administration clinical trial status and regulatory milestones reported and forecast sales by country through 2034 cost estimates and regional pricing variations patent and generic entry analysis SWOT analysis and analyst views a competitive assessment of emerging therapies
Country-level forecasts are provided for the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment